VX1

by Volta Medical  · Based in France → — Transforming EP Data into AI Solutions
Cardiology

Contact for pricing
Regulatory Status Disclosed

Overview

VX1 by Volta Medical is an artificial intelligence-based decision-support software designed to assist cardiac electrophysiologists during catheter ablation procedures. The system is built for use in electrophysiology (EP) laboratories and clinical environments where complex cardiac arrhythmias, such as persistent atrial fibrillation (AF) and atrial tachycardia (AT), are diagnosed and treated.

The software integrates into the clinical workflow by analyzing intracardiac electrograms (EGMs) in real time. It automatically identifies and annotates areas of spatiotemporal dispersion, which are localized electrical abnormalities that can act as drivers for arrhythmias. By providing real-time visual annotations on 3D anatomical and electrical maps of the human atria, VX1 helps operators locate specific regions of interest.

Notable capabilities of VX1 include:

  • Real-Time Dispersion Detection: Employs machine learning and deep learning algorithms to identify and tag dispersed electrograms during mapping.
  • Broad Compatibility: Integrates with major 3D mapping systems, EP recording systems, and standard multipolar mapping catheters.
  • Booster Mode: Allows operators to increase software sensitivity during slow atrial fibrillation or atrial tachycardia to refine signal analysis.
  • Standardized Mapping: Offers a consistent, data-driven approach to mapping, reducing operator-dependent variability in identifying complex atrial signals.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-guided real-time identification of dispersed electrograms (EGMs)
  • Assists cardiologists during AFib and atrial tachycardia ablation procedures
  • Analyzes 3D anatomical and electrical maps of human atria
  • Compatible with most EP recording, 3D navigation systems, and mapping catheters
  • Designed to reduce inter-operator variability and standardize outcomes
  • Provides cycle length estimation from electrograms
  • Booster mode for increased sensitivity during AT or slow AF

Use Cases

  • Assisting electrophysiologists during catheter ablation for persistent atrial fibrillation
  • Improving outcomes in complex atrial fibrillation and atrial tachycardia treatments
  • Real-time identification of arrhythmia drivers during procedures
  • Standardizing electrogram-based ablation outcomes across operators and centers

What Physicians Need to Know

ECG/EKG Analysis Capability
VX1 analyzes intracardiac electrograms (EGMs) in real-time during cardiac ablation procedures, specifically identifying 'dispersed electrograms' associated with atrial fibrillation (AFib) and atrial tachycardia (AT). It provides cycle length estimation from electrograms recorded with mapping and coronary sinus catheters.
Arrhythmia Detection Accuracy
The software assists in the real-time identification of abnormal electrograms, which are indicative of arrhythmia drivers. Studies have shown that VX1-guided ablation led to AF termination in 88% of patients and a high freedom from AF (89%) and any atrial arrhythmia (73%) after a one-year follow-up, with an average of 1.3 procedures per patient. It standardizes the identification of abnormal electrograms across centers and operators.
Cardiac Monitoring Integration
VX1 is compatible with most readily available multipolar catheters and existing electrophysiology (EP) recording and 3D navigation systems, allowing for integration into current operating room or EP lab workflows. It processes electrogram information directly from catheter-based recording systems.
AHA/ACC Guideline Alignment
Volta Medical's AI companion technology and the TAILORED-AF clinical trial have been featured in the latest consensus statement from leading international cardiac electrophysiology societies (EHRA/HRS/APHRS/LAHRS) on atrial fibrillation ablation, providing clinical advice aligned with advancements in managing AF treatments.
Real-Time Alert Capability
VX1 provides real-time visual and sound cues to operators, representing algorithmic adjudication for the presence or absence of dispersed electrograms. It assists in the real-time manual or automatic annotation of 3D anatomical and electrical maps of the human atria during ablation procedures.
Physician Tip

VX1 is designed to assist electrophysiologists by providing real-time, objective identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. This can help standardize EGM-based ablation outcomes, potentially reducing inter-operator variability and improving the efficacy of procedures by more precisely pinpointing optimal ablation locations. While the clinical significance for catheter ablation of atrial arrhythmias has not yet been fully established by clinical investigations, ongoing trials like TAILORED-AF aim to demonstrate its impact.

VX1 is built for broad compatibility, working with most commercially available multipolar catheters and various EP recording and 3D navigation systems. This flexibility allows for seamless integration into existing electrophysiology lab setups and workflows. The VX1+ iteration offers enhanced integration with systems like Abbott Laboratories' EnSite X mapping system and compatibility with Biosense Webster's Octaray multi-polar mapping catheter.

Details

Category Cardiology AI, Surgical AI
Pricing Contact for pricing
DeploymentSoftware integrated with existing electrophysiology (EP) lab mapping and recording systems.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The VX1 software is U.S. FDA 510(k) cleared (K201298) and European CE Mark approved. It assists operators in the real-time manual annotation of 3D anatomical and electrical maps of human atria for the presence of multipolar intra-cardiac atrial electrograms exhibiting spatiotemporal dispersion during atrial fibrillation or atrial tachycardia.

Integrations
EHR Not specified
Specialties Cardiology

What the Web Says

Volta Medical's VX1 is an AI-powered software designed to assist electrophysiologists in real-time during atrial fibrillation (AFib) ablation procedures. It aims to standardize the identification of abnormal electrograms (EGMs) and improve treatment outcomes for patients with persistent AFib. The software has received FDA clearance and CE mark, and initial studies suggest it can lead to high rates of freedom from AFib after ablation.

Overall: Positive

Strengths

  • Reproduces expert-physician EGM analysis, standardizing abnormal electrogram detection across different operators and centers.
  • Assists physicians in real-time identification of specific abnormal electrograms (dispersed EGMs) during ablation procedures.
  • Shows promise in potentially reducing inter-operator variability in procedural data analysis.
  • May lead to improved patient outcomes with high rates of freedom from AFib and atrial arrhythmia after one year.
  • Compatible with most readily available multipolar catheters and mapping technologies.
  • Intuitive and user-friendly interface with visual and sound cues for operators.

Limitations

  • Clinical significance of utilizing VX1 to identify areas with spatiotemporal dispersion for catheter ablation has not been fully established by clinical investigations.
  • The ongoing TAILORED-AF trial is expected to confirm the potential of the technology and establish it as a new standard of care, indicating that this is still a developing area.
  • No specific negative reviews from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra were found in the search results.

Based on reviews from: PRNewswire, BioWorld, BioSpace, Cardiac Rhythm News, Medium, Journal of Cardiovascular Electrophysiology (via PMC)

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate VX1

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
VOLTA MEDICAL's VX1 AI software for use in atrial fibrillation mapping now FDA cleared
Volta Medical announced FDA clearance for its VX1 AI software, the first AI-based tool in interventional cardiac electrophysiology, designed to assist in real-time annotation of 3D anatomical and electrical maps during atrial fibrillation or atrial tachycardia.
2020-12
BioWorld
Volta Medical raises $28M for AI-based interventional cardiac electrophysiology tool
Volta Medical secured $28 million in Series A funding for its VX1 software mapping system, an AI algorithm compatible with existing catheters and technology for treating cardiac arrhythmia.
2021-02
GlobeNewswire
Volta Medical VX1 AI Software to be Featured at Heart Rhythm 2022
Volta Medical announced its participation at Heart Rhythm 2022, where its VX1 digital AI companion technology would be featured in several sessions and at their exhibit booth, including a demonstration of the upcoming VX1+ software upgrade.
2022-04
BioSpace
Volta Medical's AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
Volta Medical announced the publication of peer-reviewed results from its Ev-AIFib-Proof-of-Concept-Study with VX1 in the Journal of Cardiovascular Electrophysiology, demonstrating the software's ability to assist in real-time identification of abnormal electrograms during AF procedures.
2022-08
Gilde Healthcare
Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation
Gilde Healthcare highlighted Volta Medical's peer-reviewed publication in the Journal of Cardiovascular Electrophysiology, detailing the successful Ev-AIFib Study and the use of VX1 for standardizing EGM-guided ablation in persistent AF patients.
2022-09
Business Wire
Volta Medical Secures u20ac36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
Volta Medical announced u20ac36 million in Series B funding, led by Vensana Capital, to accelerate new product development, support clinical trials, and prepare for US commercialization of its VX1 AI decision-support software.
2023-01
Volta Medical
Volta AF-Xplorer FDA Cleared
Volta Medical announced FDA clearance for Volta AF-Xplorer, an AI companion for assessing complex AF and atrial tachycardia procedures, and highlighted the completion of enrollment for the TAILORED-AF trial.
2023-05
Volta Medical
Volta Medical Receives CE Mark for AF-Xploreru2122 Decision support solution to Simplify Complex Atrial Fibrillation Procedures
Volta Medical received CE Mark for its Volta AF-Xploreru2122, an enhanced version of the VX1 device, enabling its sale and distribution in the European Union for real-time annotation of spatiotemporal dispersions during AF and atrial tachycardia procedures.
2024-02

Videos

Product demos, reviews, and walkthroughs for VX1.

View all on YouTube

Frequently Asked Questions

Volta Medical's VX1 AI software is designed to integrate seamlessly with most multipolar catheters and existing technologies in electrophysiology labs. Its specific role is to assist operators in the real-time manual annotation of 3D anatomical and electrical maps of the human atria during atrial fibrillation (AFib) or atrial tachycardia, by identifying specific electrograms known as dispersed electrograms. This helps physicians locate heart regions with abnormal electrograms to guide ablation interventions.
Volta Medical's VX1 AI software has received FDA clearance in the US and a CE mark in the European Union, making it the first FDA-cleared AI-based tool in interventional cardiac electrophysiology. While specific VX1 data privacy details are not provided, healthcare AI tools generally adhere to stringent regulations like HIPAA and GDPR, employing robust encryption, access controls, and audit trails to safeguard sensitive patient information.
VX1 differentiates itself by offering real-time, AI-driven analysis of electrograms to identify spatiotemporal dispersion, which aims to provide a more accurate and reliable way to pinpoint zones of interest compared to traditional manual methods. It shows promise in potentially reducing inter-operator variability in the analysis of procedural data. While other AI solutions exist in healthcare, VX1 is specifically tailored for interventional cardiac electrophysiology for AFib mapping.
Specific pricing details for Volta Medical's VX1 are not publicly available in the search results. However, pricing models for healthcare AI solutions commonly include tiered subscription structures based on usage or features, initial implementation costs for integration with existing systems, and ongoing support or maintenance fees. These costs can vary significantly depending on the scale of deployment and specific contractual agreements.
A key caveat for VX1 is that the clinical significance of utilizing the software to help identify areas with intra-cardiac atrial electrograms exhibiting spatiotemporal dispersion for catheter ablation of atrial arrhythmias has not yet been established by clinical investigations. Like other AI tools, VX1 is intended as a decision-support tool and does not replace human clinical judgment, and may have limitations related to data biases or generalizability.
Yes, there are ongoing efforts to further evaluate VX1. Several US hospitals have implemented VX1 and are recruiting AF ablation patients to participate in an international, randomized controlled clinical trial. This trial aims to evaluate the outcomes of VX1-guided ablation versus standard ablation procedures to establish its clinical significance and long-term efficacy.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from Volta Medical

Volta AF-Xplorer
Volta Medical
Cardiology AI
Volta AF-Xplorer is an AI-assisted mapping and decision-support system for electrophysiology ablation procedures, automatically detecting dispersed electrograms in real-time to guide treatment for complex atrial fibrillation and atrial tachycardia.
Volta AF-Xplorer II
Volta Medical
Cardiology AI
Volta AF-Xplorer II is an AI-powered digital companion from Volta Medical, designed to assist electrophysiologists in the real-time identification of spatio-temporal dispersed electrograms during complex atrial fibrillation and atrial tachycardia ablation procedures.
VX1+
Volta Medical
Cardiology AI
AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.